Optimal follow-up for melanoma

Speijers, M.J.; Francken, Anne Brecht; Hoekstra-Weebers, Josette E. H. M.; Bastiaannet, E.; Kruijff, Schelto; Hoekstra, Harald J.

doi:10.1586/edm.10.38

Cited by 15 publications

(22 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a recent review article by Speijers et al. citing 19 mostly European melanoma follow‐up guidelines (15 of which were published in 2006 or later) was used to source guidelines that might not have been indexed in the standard databases.…”

Section: Methodsmentioning

confidence: 99%

“…A search of 11 electronic databases and websites was conducted in February 2013 to identify potentially relevant guidelines: EMBASE; PubMed (Medline); Australian Government National Health and Medical Research Council (NHMRC) Guidelines Portal; National Guidelines Clearinghouse (NGC); GIN Library; Ontario Guideline Advisory Committee (GAC); Canadian Agency for Drugs and Technology in Health (CADTH); National Health Services (NHS) Guidelines Finder; Royal College of Physicians (RCP) Guideline Database; National Institute of Health and Clinical Excellence (NICE); New Zealand Guidelines Group (NZGG) and Scottish Intercollegiate Guidelines Network (SIGN). In addition, a recent review article by Speijers et al (14) citing 19 mostly European melanoma follow-up guidelines (15 of which were published in 2006 or later) was used to source guidelines that might not have been indexed in the standard databases.…”

Section: Selection Of Cutaneous Melanoma Follow-up Guidelinesmentioning

confidence: 99%

See 1 more Smart Citation

To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?

et al. 2014

View full text Add to dashboard Cite

BackgroundClinical practice guidelines should aim to assist clinicians in making evidence-based choices in the care of their patients. This review attempts to determine the extent of evidence-based support for clinical practice guideline recommendations concerning cutaneous melanoma follow up and to evaluate the methodological quality of these guidelines.MethodsCurrent guidelines providing graded recommendations regarding patient follow up were identified through a systematic literature review. The authors reviewed the evidence base used to formulate recommendations in each of the guidelines and appraised the quality of the guidelines using the AGREE II (Appraisal of Guidelines for Research and Evaluation) instrument.ResultsMost guideline recommendations concerning the frequency of routine skin examinations by a clinician and the use of imaging and diagnostic tests in the follow up of melanoma patients were based on low-level evidence or consensus expert opinion. Melanoma follow-up guidelines are of variable methodological quality, with some guidelines not recommended by the appraisers for use in clinical practice.ConclusionClinicians should be aware of how scant the evidence base is for many recommended courses of action. As a consequence of the paucity of evidence in the field of melanoma follow up, there is considerable variability in the guidance provided. The variable methodological quality of guidelines for melanoma follow up could be improved by attention to the criteria described in AGREE II.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Selection Of Cutaneous Melanoma Follow-up Guidelinesmentioning

confidence: 99%

To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The results demonstrated that PET was superior to MRI and CT for sensitivity, specificity, and accuracy in detecting pelvic nodal metastasis (10, 11). The role of PET for staging and re-staging cutaneous malignant melanoma has been reported to have high sensitivity and accuracy, and was most valuable for patients in clinical stage IIC and higher (12, 13). However, no reports have been published about the role of PET or PET/CT in the clinical management of malignant melanomas arising from female reproductive organs.…”

Section: Discussionmentioning

confidence: 99%

Uterine cervical melanoma presenting with rapid progression detected by PET/CT

Tsai

Shueng

Chan

et al. 2012

Acta Radiologica Short Reports

View full text Add to dashboard Cite

Malignant melanoma of the uterine cervix is a rare extracutaneous melanoma which develops aggressively and is associated with a bleak prognosis. To our knowledge, no prior published reports have discussed the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) in managing this disease. Our case study involved a 66-year-old woman with a malignant melanoma of the uterine cervix. The patient received PET/CT that identified metastases and lesions which had not been detected from her MRI. Serial PET/CT elucidated that the disease was initially limited to the pelvis, but then metastasized to the abdominal para-aortic lymph nodes, followed by extensive metastases to the brain, lungs, breast, supraclavicular, neck, and other abdominal lymph nodes, as observed at 6-month follow-up. PET/CT was used to complement conventional anatomic imaging modalities, and provided a novel modality for whole body screening. Visualization of the metabolic activity of indeterminate lesions may help in staging, re-staging, treatment planning, and prognostic prediction for patients with this rare disease.

show abstract

“…The serum concentration of S‐100B is correlated with disease stage, and S‐100B is an independent predictor of melanoma prognosis in patients undergoing therapeutic lymph node dissection (TLND) for nodal macro‐metastases . German melanoma follow‐up guidelines added the melanoma biomarker S‐100B and Italian guidelines added both S‐100B and fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning, in addition to regular patient history and physical examination . Specifically, S‐100B measurement has been recommended for use in some follow‐up guidelines in the selection of stage III patients to undergo FDG PET/CT scanning.…”

Section: Introductionmentioning

confidence: 99%

“…6,7 German melanoma follow-up guidelines added the melanoma biomarker S-100B and Italian guidelines added both S-100B and fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning, in addition to regular patient history and physical examination. 8,9 Specifically, S-100B measurement has been recommended for use in some follow-up guidelines in the selection of stage III patients to undergo FDG PET/CT scanning. However, the added value of this screening is unknown.…”

Section: Introductionmentioning

confidence: 99%

S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients

Deckers

Wevers

Kobold

et al. 2019

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Background and ObjectivesThis current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients.MethodsThis study included 100 stage III melanoma patients in follow‐up after curative lymph node dissection. Follow‐up visits included physical examination and S‐100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or elevated S‐100B.ResultsOf 100 patients, 13 (13%) had elevated S‐100B without clinical symptoms, of whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty‐six patients (26%) had clinical symptoms with normal S‐100B and FDG PET/CT revealed metastasis in 20 (77%). Three patients had clinical symptoms and elevated S‐100B, and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated S‐100B prompted early detection of asymptomatic disease; 10% of all asymptomatic patients in follow‐up, 23% of all patients with recurrent disease.ConclusionS‐100B cannot exclude recurrent disease during follow‐up of stage III melanoma. However, adding S‐100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma.

show abstract

Optimal follow-up for melanoma

Cited by 15 publications

References 130 publications

To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?

To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?

Uterine cervical melanoma presenting with rapid progression detected by PET/CT

S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients

Contact Info

Product

Resources

About